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Abstract
Bacteriocins are antimicrobial peptides generally active against bacteria closely related to the producer. Escherichia coli
produces two types of bacteriocins, colicins and microcins. The in vitro efficacy of isolated colicins E1, E6, E7, K and M, was
assessed against Escherichia coli strains from patients with bacteraemia of urinary tract origin. Colicin E7 was most effective,
as only 13% of the tested strains were resistant. On the other hand, 32%, 33%, 43% and 53% of the tested strains exhibited
resistance to colicins E6, K, M and E1. Moreover, the inhibitory activity of individual colicins E1, E6, E7, K and M and
combinations of colicins K, M, E7 and E1, E6, E7, K, M were followed in liquid broth for 24 hours. Resistance against
individual colicins developed after 9 hours of treatment. On the contrary, resistance development against the combined
action of 5 colicins was not observed. One hundred and five E. coli strains from patients with bacteraemia were screened by
PCR for the presence of 5 colicins and 7 microcins. Sixty-six percent of the strains encoded at least one bacteriocin, 43% one
or more colicins, and 54% one or more microcins. Microcins were found to co-occur with toxins, siderophores, adhesins and
with the Toll/Interleukin-1 receptor domain-containing protein involved in suppression of innate immunity, and were
significantly more prevalent among strains from non-immunocompromised patients. In addition, microcins were highly
prevalent among non-multidrug-resistant strains compared to multidrug-resistant strains. Our results indicate that
microcins contribute to virulence of E. coli instigating bacteraemia of urinary tract origin.
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Introduction
Antibiotic resistance of bacterial pathogens is one of the greatest
global threats to public health care. To prevent selection and
dissemination of resistance, the use of traditional antibiotics must
be limited and alternative effective therapies must be sought [1].
Of high potential are bacteriocins, ribosomally synthesized
proteinaceous compounds that are generally active against
bacteria closely related to the producer [2,3,4,5].
Escherichia coli is known to produce two types of bacteriocins,
classified by their molecular weight into colicins (25-80 kDa) and
microcins (,10 kDa). Colicins and microcins are similar in many
ways, but in contrast to colicins, microcin synthesis is not lethal to
the producing strain and is not regulated by the DNA damage
inducible SOS system. Further, almost all colicins are plasmid
encoded, whereas microcin encoding genes are also found on the
chromosome. Colicins act by either: (i) membrane permeabiliza-
tion, (ii) nuclease activity or (iii) inhibition of peptidoglycan and
lipopolysaccharide O-antigen synthesis [6]. Their activity requires
binding to a specific receptor in the outer membrane and
translocation through the outer membrane to the target by the
Tol or TonB machinery [7]. On the other hand, microcins have
been classified according to the presence, nature and localization
of post-translational modifications, gene cluster organization, and
leader peptide sequences. Class I microcins are peptides with a
molecular mass below 5 kDa, and are subjected to extensive post-
translational modifications (B17, C7 and J25). Class II microcins
are higher molecular mass peptides (5-10 kDa), and are subdivided
into two subclasses: class IIa microcins which may contain
disulfide bonds but no further post-translational modifications (L,
ColV and 24), and class IIb linear microcins that have a C-
terminal posttranslational modification by the attachment of
catechol of the salmochelin type (E492, H47, I47 and M) [8].
E. coli strains belong to the commensal intestinal flora however,
particular strains are the causative agents of serious intestinal and
extraintestinal infections [9]. In addition, E. coli strains cause
postweaning diarrhea (PWD) and edema disease in swine [10].
Extraintestinal pathogenic E. coli strains (ExPEC) are a common
cause of urinary tract infections, neonatal meningitis, osteomye-
litis, pneumonia, surgical site infections, skin and soft tissue
infections (SSTI) and bacteraemia. Virulence factors produced by
ExPEC namely, adhesins, siderophores, toxins, such as a-
hemolysin and cytotoxic necrotizing factor, as well as proteins
impairing the innate immune response, such as TcpC, facilitate
bacterial growth and persistence in the host [11,12,13,14].
Bacterial bacteraemia and septicaemia represent a significant
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28769emerging clinical problem. More than 40% of bacteraemia cases,
community and hospital acquired, are instigated by pathogenic E.
coli strains and represent the main cause of mortality as well as a
large economic burden. Most cases of E. coli septicaemia are
secondary to urinary tract infection.
The aim of the present study was to investigate the in vitro
inhibitory activity of several isolated colicins requiring distinct
receptor/translocation systems and exhibiting different mechanisms
of action namely, colicin M inhibiting peptidoglycan synthesis, E6
instigating hydrolysis of rRNA, E7 cleaving DNA and the pore
formers E1 and K, against a collection of E. coli strains isolated from
patients with bacteraemia of urinary tract origin. We also tested the
efficacy of combined application of three (E7, K, M) and five
colicins (E1, E6, E7, K, M), respectively. In addition, to gain further
insight into the role bacteriocins play among natural E. coli
populations, we studied their prevalence among the investigated
strains as well as associations of microcins with virulence factor
genes, phylogenetic group, multidrug resistance (MDR) and
epidemiology. Our results showed that only combinations of
colicins exhibited effective antimicrobial activity, precluding
evolution of resistance and that, microcins may contribute to
development of E. coli bacteraemia of urinary tract origin.
Results and Discussion
Sensitivity of uroseptic E. coli strains to colicins
Testing the isolated colicins against 105 E. coli strains from
patients with bacteraemia of urinary tract origin, revealed that
colicin E7 was most effective, as 87% of the tested strains were
susceptible. On the other hand, 32%, 33%, 43% and 53% of the
tested strains exhibited resistance to colicins E6, K, M and E1,
respectively (Fig 1). However, among susceptible E. coli strains
various levels of susceptibility were observed (Fig 1). As noted
previously, variable levels of susceptibility to colicins could be due
to variability in the number of colicin receptors per cell or due to
shielding of receptors by the lipopolysaccharide O-antigenic
chains [15].
Colicins have been shown to be effective against E. coli strains
associated with diarrhea including serotype O157:H7 [16,17,
18,19,20,21,22], as well as postweaning diarrhea (PWD) and
edema disease in swine [23]. Recently, dietary inclusion of
colicin E1 was shown to decrease the incidence and severity of
PWD caused by F18-positive enterotoxigenic E. coli (ETEC) [24].
Additionally, colicins have been shown to prevent colonization of
urinary catheters [25] and to be effective against uropathogenic
strains [26]. Colicin E1 was also shown to exhibit inhibitory
activity against Listeria monocytogenes, the causative agent of human
listeriosis in broth culture and in ready-to-eat (RTE) products
[27], while colicins H and G were shown to exhibit inhibitory
activity against Salmonella strains isolated from clinical cases [28].
Colicins are without doubt effective against pathogens neverthe-
less, variable susceptibility as well as resistant strains have been
described [23,26]. Due to the high prevalence of resistances
against the isolated colicins we subsequently tested the efficacy of
a combination of five of the selected colicins, namely E1, E6, E7,
K and M. The combined action of the five colicins was effective
against 98% of the tested strains as only 2% were resistant.
Bacterial growth inhibition with colicin cocktail
The inhibitory activity of individual colicins E1, E6, E7, K and
M were followed in liquid broth for 24 hours. In all experiments
employing only individual colicins, an approximately five fold
increase in optical density, demonstrating regrowth, was observed
following 9 hours of treatment. After 24 hours of incubation, the
optical densities of the cultures treated with only a single colicin
were almost comparable to untreated cultures. To elucidate
whether regrowth was due to loss of colicin activity or due to
appearance of resistant bacterial cells, fresh colicins were added to
the cultures throughout the growth cycle (every three hours).
Nonetheless, an increase in optical density was detected. In
addition, cells from cultures incubated for 24 hours in the presence
of colicins were tested for colicin susceptibility on plates and in
liquid media and were shown to exhibit resistance against the
tested colicins.
Figure 1. Percentages of uroseptic E. coli strains with minimal inhibitory concentrations (MIC) for colicins E1, E6, E7, K and M.
doi:10.1371/journal.pone.0028769.g001
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or alter a colicin receptor and (ii) due to absence of a functional
system of colicin translocation. Simultaneous mutations in two or
more receptors/translocation systems are far more unlikely than
mutation of a single receptor/translocation system. Thus, to
determine whether combinations of colicins employing different
receptors, translocation systems and modes of action could provide
effective antimicrobial activity, the inhibitory activity of combina-
tions of colicins E7, K, M and E1, E6, E7, K, M was followed for
24 hours. If a combination of three colicins was employed,
regrowth was observed when fresh colicins were applied only at
the beginning/initiation of the growth cycle (inoculation of
overnight culture cultivated without colicins into fresh media with
colicins), while application every three hours throughout the
growth cycle precluded regrowth. On the other hand, no
resistance was observed when a mixture of five colicins was
applied (Fig 2). A prerequisite for validation of the efficacy of
combinations of colicins are in vivo experiments in model
organisms.
Prevalence of bacteriocin encoding genes among
uroseptic strains
To generate further insight into the roles bacteriocins play
among E. coli populations we subsequently analyzed the entire
collection of strains from patients with bacteraemia of urinary tract
origin, for one or more bacteriocins (colicins and microcins).
Previous studies have suggested that colicins promote phenotypic
and genotypic diversity within E. coli populations in the
mammalian colon [29] while microcins contribute to fitness
[30], and that the class IIb catechol microcins may act as potential
urovirulence factors [13]. The catechol microcins take advantage
of catechol receptors (Cir, Fiu or FepA) to enter E. coli cells.
Production of catechol receptors is induced in low-iron conditions,
due to which susceptible bacteria become more sensitive,
providing microcin producers a competitive advantage [31].
Sixty-six percent of the strains encoded at least one bacteriocin,
43% one or more colicins, and 54% one or more microcins. Of the
75 bacteriocin-encoding strains, 43% encoded one type of
bacteriocin, 45% two, 8% three, and 4% encoded four different
bacteriocins. Among the investigated strains nucleotide sequences
specific for colicin M were most frequent (11%), followed by
sequences for colicins E1, K, E7 (8%, 6%, 2%, respectively), while
colicin E6 sequences were not detected. Of the microcin specific
sequences, most frequent were those encoding microcin M (35%),
followed by microcin H47 (29%), microcin V (17%), microcins
B17, C7 and L (3%) and microcin J25 (1%).
E. coli strains can be assigned to one of four major phylogenetic
groups: A, B1, B2 or D [32]. Extraintestinal pathogenic E. coli
strains mainly belong to the phylogenetic group B2 and to a lesser
degree to group D [33]. Most strains encoding more than one
bacteriocin belonged to the B2 phylogenetic group while
bacteriocins were least frequent among group B1 strains
(Table 1). The majority of microcin encoding strains (72%)
belonged to the B2 group. Further, more than 85% of the strains
positive for microcin H47, more than 80% strains positive for
microcin M and more than 75% of the strains positive for
microcin V were members of the B2 group.
Analysis of bacteriocin co-occurrence revealed several statisti-
cally significant associations namely, microcins H47 and M
(P,0.0001), microcins H47 and V (P=0.0051), microcins M
and V (P=0.0024), microcins B17 and L (P=0.0032), colicin K
and microcin V (P=0.0268), colicin M and microcin M
(P=0.0067), and colicin M and microcin H47 (P=0.0417). Our
data confirm the observed frequent co-association of microcins
H47 and M [13,34,35] Recently, S ˇmajs, et al. [36] reported higher
prevalence of colicin E1 among UTI strains compared to controls
(22% and 10%) and consequently speculated that ColE1 is a
potential virulence factor. In contrast, our results showed a low
prevalence (12%) of colicin E1 encoding E. coli strains instigating
bacteraemia. Moreover, Gordon and O Brien [35] showed that,
among 102 bacteriocin producing commensal E. coli strains, 22 %
Figure 2. Effect of colicins on uroseptic strains. Effect of colicins E1, E6, E7, K and M on uroseptic strains UL209 (a) and UL141 (b). All colicins
were added to the final concentration 1 mg/ml. Control represents the bacterial culture without colicin. * colicins were applied only at the beginning
of the growth cycle; ** colicins were applied throughout the growth cycle.
doi:10.1371/journal.pone.0028769.g002
Table 1. Frequency of E. coli strains encoding multiple
bacteriocins with respect to phylogenetic group (groups A,
B1, B2, D).
Number of encoded
bacteriocins Frequency (%)
A(n=16) B1 (n=14) B2 (n=54) D (n=21)
No bacteriocin 56 43 11 43
One bacteriocin 25 43 28 33
Two or more bacteriocins 19 14 61 24
doi:10.1371/journal.pone.0028769.t001
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geographical variations or host characteristics [37].
Association of microcins with virulence factors
A number of urovirulence factors (adhesins, cytotoxins, side-
rophores, etc.) have been identified, which appear more
frequently in uropathogenic E. coli than in commensal or
enteropathogenic strains [11,12]. In addition, two recent studies
have proposed four microcins (E429, H47, I47 and M) as
potential urovirulence factors, since their production or the
presence of their corresponding genes occurred predominantly in
UPEC strains [30,31]. By assay for the prevalence of tcpC,
encoding the Toll/Interleukin-1 receptor domain-containing
protein, and employing our previously published data on the
prevalence of 14 virulence genes [12] among the investigated
bacteraemic strains, we examined their co-occurrence with
microcin encoding genes. Microcins were found to co-occur with
toxins (hlyA, P=0.0014; cnf1, P=0.0341; usp, P,0.0001), side-
rophores (iroN, P=0.0029; iroCD, P=0.0029; fyuA, P=0.0007)
adhesins (sfa, P,0.0001; papC, P=,0.0001; papG, P=0.0013)
and the Toll/Interleukin-1 receptor domain-containing protein
(tcpC P=0.0003). Of the individual investigated microcins,
microcin H47 was strongly associated with toxins (hlyA,
P=0.0009; cnf1, P=0.0014; usp, P,0.0001), the fyuA siderophore
(P=0.0056), adhesins sfa (P,0.0001), papC( P=0.0002) and papG
(P,0.0001) as well as tcpC (P=0.0002); microcin M was
associated with toxins (hlyA, P=0.0001; cnf1, P=0.0014; usp,
P,0.0001), the fyuA siderophore (P=0.0003), adhesins sfa
(P,0.0001), papC( P=0.0002) and papG( P,0.0001) as well as
tcpC (,0.0001); ColV was associated with siderophores iroN
(P=0.0002) and iroCD (P=0.0002), and adhesins sfa (P=0.0058)
and papC( P=0.0400); microcins B17 and L were associated with
adhesin papG( P=0.0234). Furthermore, strains encoding two
microcins, namely H47 and M, were more likely to encode toxins
(hlyA, P=0.0004; cnf1, P=0.0010; usp, P,0.0001), siderophores
(fyuA, P=0.0003; iroN, P=0.0485; iroCD, P=0.0485), adhesins
sfa (P,0.0001), papC( P=0.0004) and papG( P,0.0001) as well as
tcpC (0.0001). Our results confirm the previous findings of
Azpiroz, et al. [13], who found strong association with various
virulence factors among strains producing both microcins, H47
and M. Our results indicate, on the basis of the distribution of
microcin encoding genes that, microcins H47 and M may
contribute to the development of bacteraemia of urinary tract
origin.
Almost all bacteria require iron [38]. Previous studies have
shown that a number of microcins are induced when iron is
limiting and that many employ receptors for iron acquisition [8].
Thus, it has been hypothesized that microcins may be involved in
competition for iron [35]. While the microcins we studied were in
general shown to be associated with siderophores, additional
experimental data are required to corroborate their role in
competition for iron.
Associations of microcins with immune status
Prior investigations have implied that a greater set/comple-
ment of virulence factors is required for bacterial invasion of a
non-immunocompromised host than of an immunocompromised
one [39,40,41,42]. Our previous study showed that usp, papC and
the adhesion-encoding sfa/foc exhibited a statistically significant
higher prevalence among strains from non-immunocompromised
patients with bacteraemia of urinary tract origin [12]. To resolve
whether microcin production is significant for invasion of the
bloodstream, we analysed the prevalence of bacteriocins and their
co-associations with virulence factors among patients with
different immune status. Comparison of microcin prevalence
among immunocompromised and non-immunocompromised
patients revealed that their presence was significantly higher
among isolates from non-immunocompromised patients (82% vs.
49%, P=0.0304). Further, analysis of microcins and their co-
associations with other virulence factors revealed that co-
occurrences of microcins with toxins (usp), siderophores (iroN,
iroCD, iucD) and adhesins (papC, sfa, fimH) were statistically
significantly more frequent among strains from non-immuno-
compromised patients (Table 2).
A number of studies have indicated that antibiotic-susceptible
and -resistant ExPEC isolates are fundamentally different bacterial
populations [12,43,44,45,46,47]. Antibiotic-susceptible strains
mostly belong to the B2 phylogenetic group which are character-
istically associated with higher virulence factor potential repertoire
than antibiotic-resistant strains, which are typically associated with
groups D and A. We therefore investigated associations between
MDR (multidrug resistance) status and co-occurrence of microcins
with virulence factors. Our analysis revealed that microcins were
highly prevalent among non-MDR strains compared to MDR
strains (63% vs. 23%, P=0.0014). All 30 strains harbouring
microcin H47 were non-MDR (P=0.0003). In addition, 34 out of
37 strains harbouring microcin M were non-MDR (P=0.0227),
and 17 out of 18 ColV harbouring strains were non-MDR.
Analysis of microcins and their co-associations with other
virulence factors revealed that co-occurrences of microcins with
toxins (usp, hlyA), siderophores (iroN, iroCD, fyuA, iucD) and
adhesins (papC, sfa, fimH) were statistically significantly more
frequent among non-MDR strains (Table 2). Our results agree
with the proposition that a decreased prevalence of virulence traits
among resistant strains is a possible trade-off between resistance
and virulence in ExPEC [48] and further corroborate that
microcins are potential virulence factors significant in bacteraemia
of urinary tract origin.
Moreover, strains from non-nosocomial infections were more
likely to encode microcin and the Toll/Interleukin-1 receptor
domain-containing protein (tcpC P=0.011) than strains from
nosocomial infections. Strains from non-nosocomial infections
were also more likely to encode microcin and other virulence traits
than strains from nosocomial infections however, these differences
were not statistically significant (Table 2). Similar results were
provided by a recent study of community-acquired, health care-
associated and nosocomially acquired E. coli strains causing
bacteraemia [47], where the authors had shown that nosocomial
E. coli strains have reduced virulence factor content and a higher
frequency of MDR.
In conclusion, our results show that application of a cocktail/
mixture of three/five colicins throughout the growth cycle
effectively inhibits growth of pathogenic E. coli strains and prevents
appearance of resistance. In addition, our results indicate that
microcins contribute to virulence of Escherichia coli instigating
bacteraemia of urinary tract origin.
Materials and Methods
Strain collection
The E. coli strain collection investigated in this study has been
described previously [12]. The collection consists of 105 E. coli
strains from patients with bacteraemia of urinary tract origin,
isolated at the Institute of Microbiology and Immunology, Medical
Faculty, University of Ljubljana, from patients admitted to various
departments of the University Medical Center in Ljubljana, from
2000 and 2001.
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Co-association Associated host characteristic [no. of isolates (%)]
Non-
immunocompro-
mised (n=17)
Immunocom-
promised
(n=88) P value
Nosocom-ial
(n=24)
Non-
nosocomial
(n=81) P value
MDR
(n=22)
Non-MDR
(n=83) P value
usp microcins 10 (59) 19 (22) 0.006 4 (17) 25 (31) NS 0 (0) 29 (35) ,0.001
H47 7 (41) 17 (19) 0.062* 4 (17) 20 (25) NS 0 (0) 24 (29) 0.003
mcmM 8 (47) 17 (19) 0.026 4 (17) 21 (26) NS 0 (0) 25 (30) 0.002
V 3 (18) 4 (5) NS 1 (4) 6 (7) NS 0 (0) 7 (8) NS
hlyA microcins 5 (29) 17 (19) NS 5 (21) 17 (21) NS 1 (5) 21 (25) 0.039
H47 4 (24) 11 (13) NS 3 (13) 12 (15) NS 0 (0) 15 (18) 0.037
mcmM 4 (24) 14 (16) NS 3 (13) 15 (19) NS 1 (5) 17 (20) NS
V 1 (6) 3 (3) NS 2 (8) 2 (2) NS 0 (0) 4 (5) NS
cnf1 microcins 4 (24) 7 (8) 0.056* 2 (8) 9 (11) NS 0 (0) 11 (13) NS
H47 3 (18) 6 (7) NS 2 (8) 7 (9) NS 0 (0) 9 (11) NS
mcmM 3 (18) 7 (8) NS 2 (8) 8 (10) NS 0 (0) 10 (12) NS
V 1 (6) 0 (0) NS 0 (0) 1 (1) NS 0 (0) 1 (1) NS
tcpC microcins 4 (24) 14 (13) NS 0 (0) 18 (22) 0.011 0 (0) 18 (22) 0.012
H47 3 (18) 10 (11) NS 0 (0) 13 (16) 0.036 0 (0) 13 (16) 0.065*
mcmM 4 (24) 13 (15) NS 0 (0) 17 (21) 0.011 0 (0) 17 (20) 0.020
V 1 (6) 2 (2) NS 0 (0) 3 (4) NS 0 (0) 3 (4) NS
iroN microcins 11 (65) 29 (33) 0.027 7 (29) 33 (41) NS 3 (14) 37 (45) 0.0125
H47 7 (41) 14 (16) 0.041 3 (13) 18 (22) NS 0 (0) 21 (25) 0.006
mcmM 8 (47) 17 (19) 0.026 3 (13) 22 (27) NS 1 (5) 24 (29) 0.022
V 4 (24) 13 (15) NS 4 (17) 13 (16) NS 1 (5) 16 (19) NS
iroCD microcins 11 (65) 29 (33) 0.027 7 (29) 33 (41) NS 3 (14) 37 (45) 0.012
H47 7 (41) 14 (16) 0.041 3 (13) 18 (22) NS 0 (0) 21 (25) 0.006
mcmM 8 (47) 17 (19) 0.026 3 (13) 22 (27) NS 1 (5) 24 (29) 0.022
V 4 (24) 13 (15) NS 4 (17) 13 (16) NS 1 (5) 16 (19) NS
fyuA microcins 12 (71) 38 (43) 0.061* 8 (33) 42 (52) NS 3 (14) 47 (57) ,0.001
H47 7 (41) 21 (24) NS 4 (17) 24 (30) NS 0 (0) 28 (34) 0.001
mcmM 9 (53) 26 (30) NS 4 (17) 31 (38) NS 3 (14) 32 (39) 0.040
V 4 (24) 11 (13) NS 4 (17) 11 (14) NS 0 (0) 15 (18) 0.037
papC microcins 13 (76) 32 (36) 0.003 6 (25) 39 (40) 0.060* 3 (14) 42 (51) 0.002
H47 7 (41) 18 (20) NS 4 (17) 21 (26) NS 0 (0) 25 (30) 0.002
mcmM 9 (53) 23 (26) 0.042 4 (17) 28 (35) NS 3 (14) 29 (35) 0.069*
V 5 (29) 9 (10) 0.049 3 (13) 11 (14) NS 0 (0) 14 (17) 0.038
sfa microcins 8 (47) 16 (18) 0.023 2 (8) 22 (27) 0.058* 0 (0) 24 (29) 0.003
H47 8 (47) 14 (16) 0.008 2 (8) 20 (25) NS 0 (0) 22 (27) 0.006
mcmM 8 (47) 16 (18) 0.023 2 (8) 22 (27) 0.058* 0 (0) 24 (29) 0.003
V 0 (0) 0 (0) NS 0 (0) 0 (0) NS 0 (0) 0 (0) NS
papG microcins 3 (18) 11 (13) NS 1 (4) 13 (16) NS 0 (0) 14 (17) 0.038
H47 3 (18) 9 (10) NS 1 (4) 11 (14) NS 0 (0) 12 (14) 0.067*
mcmM 3 (18) 11 (13) NS 1 (4) 13 (16) NS 0 (0) 14 (17) 0.038
V 0 (0) 0 (0) NS 0 (0) 0 (0) NS 0 (0) 0 (0) NS
K1 microcins 4 (24) 14 (16) NS 5 (21) 13 (16) NS 0 (0) 18 (22) 0.012
H47 1 (6) 5 (6) NS 1 (4) 5 (6) NS 0 (0) 6 (7) NS
mcmM 2 (12) 4 (5) NS 1 (4) 5 (6) NS 0 (0) 6 (7) NS
V 3 (18) 9 (10) NS 4 (15) 8 (10) NS 0 (0) 12 (14) 0.067*
iucD microcins 13 (76) 37 (42) 0.015 8 (33) 42 (52) NS 4 (18) 46 (55) 0.002
H47 8 (47) 20 (23) 0.068* 4 (17) 24 (30) NS 0 (0) 28 (34) ,0.001
mcmM 10 (59) 25 (28) 0.023 4 (17) 31 (38) 0.053 3 (14) 32 (39) 0.021
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The frequency of colicin production was determined using the
agar overlay method with indicator strain E. coli CL173 [49].
Briefly, agar plates were stab inoculated with the test strains and
incubated overnight at 37uC. Colonies were lysed for 15 min using
cellulose pads impregnated with chloroform. To eliminate residual
chloroform vapour the plates were then exposed to air and
overlaid with soft agar containing an indicator strain and
incubated overnight at 37uC.
PCR-based bacteriocin identification and prevalence of
tcpC
Colicin producing strains were further characterized for colicin
type using PCR-based screening with the primers described by
Gordon, et al. [35].
The entire collection of uropathogenic strains was also PCR
screened for genes encoding seven microcins and for tcpC,
encoding the Toll/Interleukin-1 receptor domain-containing
protein. The primers were described previously [14,35] while
microcin M specific sequences were detected with primers, mcmM
F: CCTGCTATGACTGCATTCATCGACATG and mcmM R:
AAACGGAAGAATGGATGATCTCGCAAA.
Colicin isolation
To isolate purified colicin M, the cma activity gene was
amplified together with the cmi immunity gene using primers
ColM1 TCACTCGAGCATGGAAACCTTAACTGTTCAT-
GCA with an added XhoI restriction site (underlined) and ColM2
CCACGCGTCCACTTCACAGTATGCTCACATTG with an
added MluI restriction site (underlined). The PCR product was
digested with restriction enzymes XhoIa n dMluI and cloned into
the expression vector pET8c [50] cut with the same two
restriction enzymes. Subsequently, colicin M was expressed in
the E. coli strain BL21 (DE3) and large-scale expression was
performed as previously described [51]. The colicin M containing
fractions, as determined by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis, were dialyzed against 5 mM phosphate
buffer and stored at –20uC.
Purified colicins E1 and K were isolated as described
previously [23,26] whereas for determination of inhibitory
activity of colicins E6 and E7, filtered supernatants of
mitomycin-C induced cells producing either colicin E6 or colicin
E7 was used. Briefly, the colicin producing strains were grown in
LB medium at 37uC until an OD600 of approximately 0.9, when
colicin production was induced by addition of mitomycin-C.
After harvest, the culture was centrifuged for 10 min at 170006g,
and the supernatant was stored at –80uC. Protein purity was
checked by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis.
Protein concentration for all isolated colicins was assayed using
a BCA (bicinchoninic acid) protein assay kit (Pierce).
In vitro inhibitory activity of the isolated colicins
The antimicrobial efficacy of the isolated colicins was assessed
against the entire collection of uropathogenic strains. To
determine the minimal inhibitory concentrations (MIC) of the
purified colicins, 5 ml of various concentrations (1, 10, and
100 mg/ml) of the selected colicins were spotted onto LB plates
overlaid with soft agar harboring the individual investigated
E. coli strains. Following overnight incubation at 37uC, the plates
were examined for colicin sensitivity observed as clear zones of
lysis of the overlaid strains. Subsequently, the inhibitory
activities of colicins E1, E6, E7, and M were quantified in
liquid broth. From each susceptibility group (corresponding to
concentrations of 1, 10 and 100 mg/ml), two strains were chosen
for the assay. Briefly, prewarmed LB was inoculated with
overnight cultures of the tested strains to an OD600 approxi-
mately 0.05. Five ml of the inoculated LB was aliquoted into
culture tubes containing either individual or combinations of
t h r e e( E 7 ,K ,M )a n df i v ec o l i c i n s( E 1 ,E 6 ,E 7 ,K ,M )a ta
concentration of 1 mg/ml. The tubes harboring the tested strains
and colicins were incubated with shaking at 37uCa n dt o
determine the inhibitory activity of the colicins, optical density
(OD600 values) was determined hourly.
Statistical analysis
Co-occurrence of two bacteriocins and one of the bacteriocins
with another virulence factor, co-association of bacteriocins,
virulence factors and host characteristics was evaluated by using
Fisher’s exact test. P-values lower than 0.05 were regarded as
statistically significant.
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Co-association Associated host characteristic [no. of isolates (%)]
Non-
immunocompro-
mised (n=17)
Immunocom-
promised
(n=88) P value
Nosocom-ial
(n=24)
Non-
nosocomial
(n=81) P value
MDR
(n=22)
Non-MDR
(n=83) P value
V 4 (24) 12 (14) NS 4 (17) 12 (15) NS 1 (5) 15 (18) NS
fimH microcins 14 (82) 42 (48) 0.015 9 (38) 47 (58) NS 5 (23) 51 (61) 0.002
H47 8 (47) 22 (25) NS 4 (17) 26 (32) NS 0 (0) 30 (36) ,0.001
mcmM 10 (59) 26 (30) 0.027 4 (17) 32 (40) 0.05 3 (14) 33 (40) 0.024
V 5 (29) 13 (18) NS 4 (17) 14 (17) NS 1 (5) 17 (20) NS
Fisher’s exact test was used for data analysis; mcmM – microcin M; * P-values near the cut-off value,0.05.
doi:10.1371/journal.pone.0028769.t002
Table 2. Cont.
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